| 2022 | 2LBA Late Breaking - Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC) | EUROPEAN JOURNAL OF CANCER |
| 2016 | A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma | EUROPEAN JOURNAL OF CANCER |
| 2022 | A novel anti-cancer compound development targeting YAP-TEAD protein-protein interaction | EUROPEAN JOURNAL OF CANCER |
| 2023 | A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)
| EUROPEAN JOURNAL OF CANCER |
| 2022 | A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study Group (UN-14–13) | EUROPEAN JOURNAL OF CANCER |
| 2012 | A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer | EUROPEAN JOURNAL OF CANCER |
| 2009 | Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer | EUROPEAN JOURNAL OF CANCER |
| 2012 | An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy | EUROPEAN JOURNAL OF CANCER |
| 2015 | An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer | EUROPEAN JOURNAL OF CANCER |
| 2017 | Application of genetically engineered Salmonella typhimurium for interferon-gamma-induced therapy against melanoma | EUROPEAN JOURNAL OF CANCER |
| 2012 | Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial | EUROPEAN JOURNAL OF CANCER |
| 2023 | Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
| EUROPEAN JOURNAL OF CANCER |
| 2021 | Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer | EUROPEAN JOURNAL OF CANCER |
| 2021 | Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis | EUROPEAN JOURNAL OF CANCER |
| 2017 | Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study | EUROPEAN JOURNAL OF CANCER |
| 2021 | Dynamic changes in circulating PD-1(+)CD8(+)T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer | EUROPEAN JOURNAL OF CANCER |
| 2020 | Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study | EUROPEAN JOURNAL OF CANCER |
| 2014 | Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency | EUROPEAN JOURNAL OF CANCER |
| 2022 | Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure | EUROPEAN JOURNAL OF CANCER |
| 2022 | Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study
| EUROPEAN JOURNAL OF CANCER |
| 2020 | First-in-human safety, pharmacokinetics, and preliminary efficacy of
TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET
| EUROPEAN JOURNAL OF CANCER |
| 2013 | Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group | EUROPEAN JOURNAL OF CANCER |
| 2022 | Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer | EUROPEAN JOURNAL OF CANCER |
| 2020 | Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial
| EUROPEAN JOURNAL OF CANCER |
| 2021 | Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study | EUROPEAN JOURNAL OF CANCER |
| 2020 | Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma | EUROPEAN JOURNAL OF CANCER |
| 2020 | Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
| EUROPEAN JOURNAL OF CANCER |
| 2017 | Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer | EUROPEAN JOURNAL OF CANCER |
| 2022 | Preclinical activity of NVL-655 in patient-derived models of ALK cancers, including those with lorlatinib-resistant G1202R/L1196M compound mutation | EUROPEAN JOURNAL OF CANCER |
| 2022 | Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial | EUROPEAN JOURNAL OF CANCER |
| 2022 | Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma
| EUROPEAN JOURNAL OF CANCER |
| 2011 | Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. | EUROPEAN JOURNAL OF CANCER |
| 2013 | Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation | EUROPEAN JOURNAL OF CANCER |
| 2017 | Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study | EUROPEAN JOURNAL OF CANCER |
| 2019 | Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer | EUROPEAN JOURNAL OF CANCER |
| 2023 | Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer | EUROPEAN JOURNAL OF CANCER |
| 2012 | The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer | EUROPEAN JOURNAL OF CANCER |
| 2022 | Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1) | EUROPEAN JOURNAL OF CANCER |
